These findings will be useful to laboratories maintaining apicomplexan parasites in vitro , especially in low-resource environments, where the high cost of commercial products creates an economic barrier for detecting and eliminating mycoplasma from culture.

Most commercial products cannot be used for clearance of mycoplasma contamination from cultures of apicomplexan parasites due to the parasites’ dependence on the apicoplast, an essential organelle with DNA replication and translation machinery of cyanobacterial origin. The lone exception, Mycoplasma Removal Agent (MRA), is relatively expensive and some mycoplasma strains have shown resistance to clearance with MRA. Here we report that the fluoroquinolone antibiotic Sparfloxacin is a safe, effective, and inexpensive alternative for treatment of mycoplasma contamination in cultures of apicomplexan parasites. Sparfloxacin cleared both MRA-sensitive and MRA-resistant mycoplasma species from P. falciparum cultures at 1 and 4 μg/mL, respectively. Furthermore, we show that cultures of three different apicomplexan parasites can be maintained at concentrations of Sparfloxacin required to clear mycoplasma without resulting in substantial deleterious effects on parasite growth.